ClinicalTrialsFinder
RecruitingNCT05461664

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors Non-exon18 Mutations of PDGFRA:A Real-world Study

Sponsor

Xinhua Zhang, MD

Enrollment

74 participants

Start Date

Jul 10, 2022

Study Type

OBSERVATIONAL

Conditions

Unresectable Solid TumorGastrointestinal Stromal TumorsRecurrent Metastatic Malignant Neoplasm

Summary

This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Patients who are aged ≥ 18 years.
  • Gastrointestinal stromal tumors confirmed by histopathological examination, and CD- and/or DOG-1-positive by immunohistochemistry.
  • Presence of mRECIST v1.1-compliant lesions with at least one measurable lesion (non-lymphadenopathy ≥1.0 cm or ≥2-fold scan slice thickness).
  • Treatment with Avapritinib.
  • Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at screening.
  • Patient informed consent and signed written consent form.
  • The patient was compliant and voluntarily scheduled for follow-up, treatment, laboratory tests, and other study procedures.

Exclusion Criteria3

  • KIT or PDGFRA wild type.
  • Failure to complete continuous atorvastatin for at least 15 days due to intolerability or disease progression.
  • Other serious acute or chronic physical or mental problems, or laboratory abnormalities, may increase the risk associated with participation in the study or use of drugs, or interfere with the judgment of the study results and, in the judgment of the investigator, are not considered appropriate for participation in the investigator.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05461664

Related Trials

GIST Oral Paclitaxel(Liporaxel)

NCT063263461 location

The Efficacy and Safety of Temozolomide in SDH-deficient GIST

NCT056616431 location

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

NCT059058871 location

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT071712031 location

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT0624477126 locations